SEATTLE — In this Healio Video Perspective from the ASRS meeting, David A. Eichenbaum, MD, FASRS, overviews the efficacy of aHtrA1 Fab for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
According to Eichenbaum, 20 mg galegenimab did not affect the rate of growth of geographic atrophy lesions at any time point in the phase 2 GAllego study, which was terminated early due to an increased rate of intraocular inflammation in participants who received galegenimab.
“We can learn from this,” he said. “We can learn that anti-HtrA1 (Read more...)